About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Depression Clinical Trials in Phoenix | 81 Studies

Clinical Trials DepressionPhoenix

Depression Clinical Trials in Phoenix

Find 81 clinical trials for depression near Phoenix, Arizona. Connect with research centers in your area.

All Depression trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 81 trials

RecruitingA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults.NCT07621237·Phoenix, Arizona and 26 others

Depression Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedEfficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant TreatmentThe purpose of this study is to assess the efficacy and safety of S47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate…NCT02805439·Plovdiv and 52 others

CompletedAn Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderThis is a multicenter, open-label, fixed dose, 26 week study of patients with MDD.NCT05061719·Phoenix, Arizona and 108 others

CompletedA Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyThe purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis…NCT03227224·Anaheim, California and 100 others

TerminatedLong-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeEvaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition…NCT02871297·Tucson, Arizona and 77 others

TerminatedA Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With AticaprantThe purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improving the depressive symptoms in…NCT06514742·Huntsville, Alabama and 83 others

CompletedMajor Depressive Disorder Study In AdultsA study to obtain safety and tolerability dataNCT00049972·Birmingham, Alabama and 70 others

CompletedEfficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionThe purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)NCT06419608·Phoenix, Arizona and 61 others

CompletedTo Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II…NCT06429722·Phoenix, Arizona and 20 others

TerminatedA Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an…NCT04855747·Homewood, Alabama and 69 others

TerminatedA Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderThis is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day)…NCT00880048·Phoenix, Arizona and 31 others

CompletedContinuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeEvaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition…NCT03108625·Targovishte and 30 others

CompletedOpen-Label Safety Study of AXS-05 in Subjects With DepressionAn open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.NCT04039022·Phoenix, Arizona and 50 others

CompletedNeuroStar TMS Therapy System: Utilization and OutcomesThe major objective of this observational study is to describe clinical outcomes of patients receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.NCT01114477·Phoenix, Arizona and 43 others

CompletedA Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant…NCT02943564·Birmingham, Alabama and 65 others

CompletedVA Augmentation and Switching Treatments for Improving Depression OutcomesThe overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step'…NCT01421342·Tuscaloosa, Alabama and 34 others

TerminatedStudy of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with…NCT03614156·Phoenix, Arizona and 51 others

RecruitingStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major…NCT06633016·Birmingham, Alabama and 49 others

CompletedA Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant TreatmentThe current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode…NCT01941043·Birmingham, Alabama and 23 others

TerminatedVortioxetine to Prevent Return of Symptoms in Children With DepressionThe purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.NCT05014919·Long Beach, California and 16 others

PreviousPage 4 of 5Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia